Search | Médecins Sans Frontières Access Campaign

53 results found
There are 3 active filters
Clear all filters
hepatitis C
sleeping sickness
Hepatitis C

53 results found

Letter |

09 August 2021

Open letter to AbbVie to make glecaprevir/pibrentasvir (G/P) accessible for people with hepatitis C

MSF sent another open letter urging AbbVie to make glecaprevir/pibrentasvir (G/P) accessible for people with hepatitis C in LMICs

Tags Hepatitis C hepatitis C glecaprevirpibrentasvir

Feature story |

25 July 2019

Generic medicines prove to be an affordable option in combating Ukraine’s hepatitis C epidemic

A combination of generic drugs coupled with a comprehensive patient support model has shown promising results in a pilot project run by Médecins Sans Frontières (MSF) in Ukraine.

Tags Hepatitis C hepatitis C sofosbuvirdaclatasvir Ukraine

Press release |

25 July 2019

Cambodia: Simpler and more affordable treatment for hepatitis C saves lives

Tags Hepatitis C hepatitis C Cambodia

Feature story

Then & Now in Access to Medicines: Changes & Challenges

Tags Hepatitis CHIV/AIDSResearch and developmentTuberculosisVaccines Ebolahepatitis CHIV/AIDSsleeping sicknesstuberculosis Access Campaign: 20 Years

Letter |

11 February 2019

Malaysia’s compulsory license for sofosbuvir is a positive step for public health and innovation

Médecins Sans Frontières (MSF) Access Campaign wrote a letter of support to the Malaysian government commending the issuance of a government use licence to enable access to an affordable version of the hepatitis C drug sofosbuvir. The ...

Tags Hepatitis C hepatitis C sofosbuvir Malaysia

Press release |

05 December 2018

Health groups appeal European Patent Office decision to uphold Gilead’s patent on hepatitis C drug

The appeal – filed by six organisations – states that the EPO should revoke Gilead’s patent on key hepatitis C drug sofosbuvir because it does not meet the requirements to be a patentable invention from a legal or scientific ...

Tags Hepatitis C hepatitis C sofosbuvir intellectual property & tradepatent opposition

Press release |

14 November 2018

MSF challenges unmerited patent for lifesaving hepatitis C medicine in China

Tags Hepatitis C hepatitis C velpatasvir China

MSF and other civil society protests in Munich at the European Patent Office against Gilead's monopoly on sofosbuvir, Germany 2018.

Press release |

26 September 2018

Brazilian court suspends Gilead's patent on hepatitis C medicine sofosbuvir

Tags Hepatitis C hepatitis C sofosbuvir intellectual property & tradepatent opposition Gilead Brazil

In March 2017, organisations from 17 European countries filed an opposition to Gilead Science's patent on the highly effective hepatitis C drug sofosbuvir. On 13th and 14th of September 2018, the hearing took e place before the European Patent Office in Munich.

Press release |

13 September 2018

MSF response to ruling in Gilead sofosbuvir patent hearing at European Patent Office

Tags Hepatitis C hepatitis C sofosbuvir generic medicinesintellectual property & trade

First set of free Hepatitis C medicines Sofosbuvir and Daclatasvir provided by Delhi Govt. run GB Pant hospital. Photograph by Garvit Nangia

Press release |

11 September 2018

Civil society groups call for end to Gilead’s unwarranted hepatitis C drug monopoly in Europe

Gilead’s price gouging for sofosbuvir blocks millions of people from getting treatment

Tags Hepatitis C hepatitis C sofosbuvir generic medicinesintellectual property & trade

Press release |

16 August 2018

Gilead loses monopoly control of its blockbuster hepatitis C medicine in China

Tags Hepatitis C hepatitis C sofosbuvir intellectual property & trade Gilead China

Feature story |

30 July 2018

Out of darkness: People living with hepatitis C

Tags Hepatitis C co-infectionhepatitis CHIV/AIDS Ukraine

Photo story

Out of darkness: A photo story

Fighting hepatitis C in Ukraine Millions of people in Ukraine continue to suffer silently through the pain of hepatitis C. Around five percent of the population live with the disease, many of whom remain untreated due to a historical ...

Tags Hepatitis C co-infectionhepatitis CHIV/AIDS Ukraine

People affected with Hepatitis C and HIV protesting at Delhi Patent Office during hearing of Sofosbuvir Patent Opposition, February 2016

Press release |

19 June 2018

MSF challenges Gilead’s unmerited patent in China for lifesaving hepatitis C medicine

The patent is being contested on the grounds that it involves well-known technologies, rendering it an unmerited patent under China’s patent law, which is consistent with the World Trade Organization rules.

Tags Hepatitis C hepatitis C sofosbuvir intellectual property & trade Gilead China

A client at the Mith Samlanh Drop-In Centre, which offers medical support, food and a resting area.

Feature story |

05 March 2018

Cambodia: Going the extra mile for people who inject drugs

Tags Hepatitis C hepatitis C

Mark Walsh, head of mission for MSF in Ukraine officially opening MSF’s project with Ivan Dudla, medical specialist from the regional health authorities in Mykolaiv.

Press release |

01 December 2017

Ukraine: People co-infected with HIV to receive hepatitis C treatment in Mykolaiv region

Tags Hepatitis C hepatitis CHIV/AIDS Ukraine

Press release |

31 October 2017

MSF secures generic hepatitis C treatment at $120 compared to $147,000 launch price tag

Tags Hepatitis C hepatitis C sofosbuvir Bristol-Myers SquibbGilead

Issue brief |

30 October 2017

Hepatitis C - Not even close

This issue brief provides information on currently available hepatitis C diagnostics and treatments, including pricing and registration information from manufacturers of direct-acting antivirals (DAAs). Reasons underlying the continued ...

Tags Hepatitis C hepatitis C sofosbuvirdaclatasvir generic medicines

Video |

28 June 2017

Armenia: Tuberculosis patient co-infected with hepatitis C benefits from new DAAs

Tags Hepatitis CTuberculosis tuberculosisdrug-resistant TBhepatitis C Armenia

Video |

16 June 2017

Cambodia – New hope for patients with hepatitis C

Tags Hepatitis C hepatitis C Cambodia

Date

Primary topics

Types of content

Products

Diseases

General Terms

Geography

Campaigns

Institutions & Events

Report series

Miscellaneous

Open letter to AbbVie to make glecaprevir/pibrentasvir (G/P) accessible for people with hepatitis C

Generic medicines prove to be an affordable option in combating Ukraine’s hepatitis C epidemic

Cambodia: Simpler and more affordable treatment for hepatitis C saves lives

Then & Now in Access to Medicines: Changes & Challenges

Malaysia’s compulsory license for sofosbuvir is a positive step for public health and innovation

Health groups appeal European Patent Office decision to uphold Gilead’s patent on hepatitis C drug

MSF challenges unmerited patent for lifesaving hepatitis C medicine in China

Brazilian court suspends Gilead's patent on hepatitis C medicine sofosbuvir

MSF response to ruling in Gilead sofosbuvir patent hearing at European Patent Office

Civil society groups call for end to Gilead’s unwarranted hepatitis C drug monopoly in Europe

Gilead loses monopoly control of its blockbuster hepatitis C medicine in China

Out of darkness: People living with hepatitis C

Out of darkness: A photo story

MSF challenges Gilead’s unmerited patent in China for lifesaving hepatitis C medicine

Cambodia: Going the extra mile for people who inject drugs

Ukraine: People co-infected with HIV to receive hepatitis C treatment in Mykolaiv region

MSF secures generic hepatitis C treatment at $120 compared to $147,000 launch price tag

Hepatitis C - Not even close

Armenia: Tuberculosis patient co-infected with hepatitis C benefits from new DAAs

Cambodia – New hope for patients with hepatitis C